Ken Griffin Navidea Biopharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.24 - $0.34 $1,848 - $2,618
-7,700 Reduced 76.24%
2,400 $0
Q4 2022

Feb 14, 2023
SELL
$0.18 - $0.3 $4,320 - $7,200
-24,000 Reduced 70.38%
10,100 $2,000
Q3 2022

Nov 14, 2022
BUY
$0.24 - $0.71 $1,896 - $5,609
7,900 Added 30.15%
34,100 $9,000

Others Institutions Holding NAVB

# of Institutions
3
Shares Held
10.4K
Call Options Held
0
Put Options Held
0
View Full List

About NAVIDEA BIOPHARMACEUTICALS, INC.

NAVB Quotes by TradingView
  • Ticker NAVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,150,900
  • Description
  • Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...
More about NAVB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email